Pinned
Today we’re sharing a defining moment for Cellular Intelligence.
We have entered into an agreement with @novonordisk to acquire STEM-PD, a Phase 2-ready allogeneic cell therapy program for Parkinson’s disease. Alongside the acquisition, Novo Nordisk is making a strategic
00:00






